Biochemistry of glycosphingolipid storage disorders: Implications for therapeutic intervention

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 358, Issue 1433, 2003, Pages 905-914

  Aerts, Johannes M ^a   Hollak, Carla ^a   Boot, Rolf ^a   Groener, Ans ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Gaucher disease; Glycosphingolipid; Lysosomal storage disorder

Indexed keywords

BIOCHEMISTRY;

EID: 0038100163     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2003.1273     Document Type: Conference Paper

References (66)

1. Abe, A., Gregory, S., Lee, L., Killen, P. D., Brady, R. O., Kulkarni, A. & Shayman, J. A. 2000 Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J. Clin. Invest. 105, 1563-1567.
2. Aerts, J. M., Van Weely, S., Boot, R., Hollak, C. E. & Tager, J. M. 1993 Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease. J. Inherit. Metab. Dis. 16, 288-291.
3. Aerts, J. M. F. G. & Hollak, C. E. M. 1997 Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin. Haematol. 10, 691-709.
4. Aerts, J. M. F. G., Donker-Koopman, W. E., Murray, G. J., Barranger, J. A., Tager, J. M. & Schram, A. W. 1986 A procedure for the rapid purification in high yield of human glucocerebrosidase using immunoaffinity chromatography with monoclonal antibodies. Anal. Biochem. 154, 655-663.
5. Aerts, J. M. F. G., Schram, A. W., Strijland, A., Van Weely, S., Jonsson, L. M. V., Tager, J. M., Sorrell, S. H., Ginns, E. I., Barranger, J. A. & Murray, G. J. 1988 Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation. Biochem. Biophys. Acta 964, 303-308.
6. Andersson, U., Butters, T. D., Dwek, R. A. & Platt, F. M. 2000 N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem. Pharmacol. 49, 821-829.
7. Ashwell, G. & Morell, A. G. 1974 The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. In Advances in enzymology, vol. 41 (ed. W. A. Wood), pp. 99-128. New York: Academic Press.
8. Barranger, J. A. & Ginns, E. I. 1989 Glycosylceramide lipidosis: Gaucher disease. In The metabolic basis of inherited disease (ed. C. R. Scriver, A. L. Beaudet, W. S. Sly & D. Vall), pp. 1677-1698. New York: McGraw-Hill.
9. Barranger, J. A. & O'Rourke, E. 2001 Lessons learned from the development of enzyme therapy for Gaucher disease. J. Inherit. Metab. Dis. 24, 89-96.
10. Barton, N. W. (and 11 others) 1991 Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. New Eng. J. Med. 324, 1464-1470.
11. Beutler, E. & Grabowski, G. A. 1995 Gaucher's disease. In The metabolic basis of inherited disease (ed. C. R. Scriver, A. L. Beaudet, W. S. Sly & D. Vall), pp. 2641-2670. New York: McGraw-Hill.
12. Blom, D., Linthorst, G. E., Spijer, D., Donker-Koopman, W. E., Strijland, A. & Aerts, J. M. F. G. 2003 Recombinant enzyme therapy of Fabry disease. Am. J. Hum. Genet. 72, 23-31.
13. Boot, R. G., Renkema, G. H., Strijland, A., van Zonneveld, A. J., Muysers, A. O. & Aerts, J. M. F. G. 1995 Cloning of cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J. Biol. Chem. 270, 26 252-26 256.
14. Boot, R. G., Renkema, G. H., Verhoek, M., Strijland, A., Bliek, J., de Meulemeester, T. M. A. M. O., Mannens, M. M. A. M. & Aerts, J. M. F. G. 1998 The human chitotriosidase gene. Nature of inherited enzyme deficiency. J. Biol. Chem. 273, 25 680-25 685.
15. Brady, R. O. 1997 Gaucher's disease: past, present and future. Baillieres Clin. Haematol. 10, 621-634.
16. Brady, R. O. 2003 Enzyme replacement therapy: conception, chaos and culmination. Phil. Trans. R. Soc. Lond. B 358, 915-919. (DOI 10.1098/rstb.2003.1269.)
17. Brady, R. O., Kanfer, J. N., Bradley, R. M. & Shapiro, D. 1966 Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. Clin. Invest. 45, 1112-1115.
18. Bijsterbosch, M. K., Donker, W., van de Bilt, H., Van Weely, S., van Berkel, T. J. & Aerts, J. M. 1996 Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. Eur. J. Biochem. 237, 344-349.
19. Butters, T. D., Mellor, H. R., Narita, K., Dwek, R. A. & Platt, F. M. 2003 Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Phil. Trans. R. Soc. Lond. B 358, 927-945. (DOI 10.1098/rstb.2003.1278.)
20. Cox, T. M. & Schofield, J. P. 1997 Gaucher's disease: clinical features and natural history. Baillieres Clin. Hematol. 10, 657-689.
21. Cox, T. M. 2001 Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J. Inherit. Metab. Dis. 24, 106-121.
22. Cox, T. M. (and 12 others) 2000 Novel oral treatment of Gaucher disease with N-butyldeoxynojirimycin to decrease substrate biosynthesis. Lancet 355, 1481-1485.
23. De Duve, C., Pressman, B. C., Gianetto, R., Wattiaux, R. & Appelmans, F. 1955 Tissue fractionation studies. Intracellular distribution patterns of enzymes in rat liver tissue. Biochem. J. 60, 604-617.
24. Dice, J. F., Terlecky, S. R., Chaing, H. L., Olsen, T. S., Isenman, L. D., Short-Russel, S. R., Freundlieb, S. & Terlecky, L. J. 1990 A selective pathway for degradation of cytosolic proteins by lysosomes. Sem. Cell Biol. 1, 449-455.
25. Erikson, A. 2001 Remaining problems in the management of patients with Gaucher disease. J. Inherit. Metab. Dis. 24, 122-126.
26. Furbish, F. S., Steer, C. J., Krett, N. L. & Barranger, J. A. 1981 Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim. Biophys. Acta 673, 425-434.
27. Gieselmann, V., Matzner, U., Klein, D., Mansson, J. E., D'Hooge, R., DeDeyn, P. D, Rauch, R. L., Hartmann, D. & Harzer, K. 2003 Gene therapy: prospects for glycolipid storage diseases. Phil. Trans. R. Soc. Lond. B 358, 921-925. (DOI 10.1098/rstb.2003.1277.)
28. Grabowski, G. A., Barton, N. W., Pastores, G., Dambrosia, J. M., Banerjee, T. K., McKe, M. A., Parker, C., Schifmann, R., Hill, S. C. & Brady, R. O. 1995 Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 122, 33-39.
29. Helenius, A. 1994 How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum. Mol. Biol. Cell 5, 253-265.
30. Hollak, C. E. M. & Aerts, J. M. F. G. 2001 Clinically relevant therapeutic endpoints in type 1 Gaucher disease. J. Inherit. Metab. Dis. 24, 97-105.
31. Hollak, C. E. M., Van Weely, S., van Oers, M. H. J. & Aerts, J. M. F. G. 1994 Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 93, 1288-1292.
32. Hollak, C. E. M., Aerts, J. M. F. G., Goudsmit, E. R., Phoa, S. S., Ek, M., Van Weely, S., von dem Borne, A. E. & van Oers, M. H. 1995 Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 345, 1474-1478.
33. Hollak, C. E. M., Maas, M., Akkerman, E., den Heeten, A. & Aerts, H. 2002 Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow response to enzyme supplementation in type 1 Gaucher disease. Blood Cell Mol. Dis. 27, 1005-1012.
34. Heitner, R., Elstein, D., Aerts, J., Van Weely, S. & Zimran, A. 2002 Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cell Mol. Dis. 28, 127-133.
35. Holzmann, E. 1989 Lysosomes. New York: Plenum Press.
36. Jeyakumar, M., Butters, T. D., Cortina-Borja, M., Hunnam, V., Proia, R. L., Perry, V. H., Dwek, R. A. & Platt, F. M. 1999 Delayed symptom onset and increased life expectancy in Sandhoff mice treated with N-butyl-deoxynojirimycin. Proc. Natl Acad. Sci. USA 96, 6388-6393.
37. Jonsson, L. M. V., Murray, G. J., Sorrell, S. H., Strijland, A., Aerts, J. M. F. G., Ginns, E. I., Barranger, J. A., Tager, J. M. & Schram, A. W. 1987 Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. Eur. J. Biochem. 164, 171-179.
38. Kornfeld, S. & Mellman, I. 1989 The biogenesis of lysosomes. A. Rev. Cell Biol. 5, 483-525.
39. Lee, L., Abe, A. & Shayman, J. A. 1999 Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 274, 14 662-14 665.
40. Linehan, S. A., Martinez-Pomares, L., Stahl, P. D. & Gordon, S. 1999 Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs. In situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia and mesanglial cells, but not dendritic cells. J. Exp. Med. 189, 1961-1972.
41. Meikle, P. F., Hopwood, J. J., Clague, A. E. & Carety, W. F. 1999 Prevalence of lysosomal storage disorders. J. Am. Med. Assoc. 281, 249-254.
42. Mistry, P. K., Wraight, E. P. & Cox, T. M. 1996 Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet 348, 1555-1559.
43. Moran, M. T., Schofield, J. P., Hayman, A. R., Shi, G.-P., Young, E. & Cox, T. M. 2000 Pathologic gene expression in Gaucher disease: upregulation of cysteine proteinases including osteoclastic catepsin K. Blood 96, 1969-1978.
44. Murray, G. J., Youle, R. J., Gandy, S. E., Zirzow, G. C. & Barranger, J. A. 1985 Purification of beta-glucocerebrosidase by preparative-scale high-performance liquid chromatography. The use of ethylene glycol-containing buffers for chromatography of hydrophobic glycoprotein enzymes. Anal. Biochem. 147, 301-310.
45. Neufeld, E. F. 1991 Lysosomal storage disorders. A. Rev. Biochem. 60, 257-280.
46. Overkleeft, H. S., Renkema, G. H., Neele, J., Vianello, P., Hung, I. O., Strijland, A., van den Burg, A., Koomen, G. J., Pandit, U. K. & Aerts, J. M. F. G. 1998 Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J. Biol. Chem. 273, 26 522-26 527.
47. Owada, M. & Neufeld, E. F. 1982 Is there a mechanism for introducing acid hydrolases into liver lysosomes that is independent of mannose-6-phosphate recognition? Evidence from I-cell disease. Biochem. Biophys. Res. Commun. 105, 814-820.
48. Patrick, A. D. 1965 A deficiency of glucocerebrosidase in Gaucher's disease. Biochem. J. 97, 17c-18c.
49. Peltonen, L. 1997 Molecular background of Finnish disease heritage. Ann. Med. 29, 553-556.
50. Peters, C. & von Figura, K. 1994 Biogenesis of lysosomal membranes. FEBS Lett. 346, 108-114.
51. Platt, F. M., Neises, G. R., Dwek, R. A. & Butters, T. D. 1994 N-butyl-deoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 269, 8362-8365.
52. Platt, F. M., Jeyakumar, M., Andersson, U., Heare, T., Dwek, R. A. & Butters, T. D. 2003 Substrate reduction therapy in mouse models of the glycosphingolipidoses. Phil. Trans. R. Soc. Lond. B 358, 947-954. (DOI 10.1098/rstb.2003.1279.)
53. Poorthuis, B. J. H. M., Wevers, R. A., Kleijer, W. J., Groener, J. E. M., de Jong, J. G. N., Van Weely, S., Niezen-Koning, K. E. & van Doggelen, O. P. 1999 The frequency of lysosomal storage diseases in The Netherlands. Hum. Genet. 105, 151-156.
54. Radin, N. S. 1996 Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj. J. 13, 153-157.
55. Renkema, G. H., Boot, R. G., Muysers, A. O., Donker-Koopman, W. & Aerts, J. M. F. G. 1995 Purification and characterisation of human chitotriosidase, a novel member of the chitinase family of proteins. J. Biol. Chem. 270, 2198-2202.
56. Renkema, G. H., Boot, R. G., Strijland, A., Donker-Koopman, W., van den Berg, M., Muysers, A. O. & Aerts, J. M. F. G. 1997 Synthesis, sorting and processing into distinct isoforms of human macrophage chitotriosidase. Eur. J. Biochem. 244, 279-285.
57. Richter, J. & Karlsson, S. 2001 Clinical gene therapy in hematology: past and future. Int. J. Hematol. 73, 162-169.
58. Rijnboutt, S., Aerts, J. M. F. G., Geuze, H. J., Tager, J. M. & Strous, G. J. 1991 Mannose-6-phosphate independent membrane association and maturation of cathepsin D, glucocerebrosidase and sphingolipid-activating protein in HepG2 cells. J. Biol. Chem. 266, 4862-4868.
59. Ringden, O., Groth, C. G., Erikson, A., Granqvist, S., Mansson, J. E. & Sparrelid, E. 1995 Ten years' experience of bone marrow transplanatation for Gaucher disease. Transplantation 56, 864-870.
60. Sandhoff, K. & Kolter, T. 2003 Biosynthesis and degradation of mammalian glycosphingolipids. Phil. Trans. R. Soc. Lond. B 358, 847-861. (DOI 10.1098/rstb.2003.1265.)
61. Stahl, P. D., Rodman, J. S., Miller, M. J. & Schlesinger, P. H. 1978 Evidence for receptor-mediated binding of glycoproteins and lysosomal glycosidases by alveolar macrophages. Proc. Natl Acad. Sci. USA 75, 1399-1430.
62. Takasaki, S., Murray, G. J., Furbish, F. S., Brady, R. O., Barranger, J. A. & Kobata, A. 1984 Structure of the N-asparagine linked oligosaccharide units of human placental glucocerebrosidase. J. Biol. Chem. 259, 10 112-10 117.
63. Van Weely, S., Aerts, J. M. F. G., van Leeuwen, M. B., Heikoop, J. C., Donker-Koopman, W. E., Barranger, J. A., Tager, J. M. & Schram, A. W. 1990b Function of oligosaccharide modification in glucocerebrosidase, a membrane-associated lysosomal hydrolase. Eur. J. Biochem. 191, 669-677.
64. Van Weely, S., van den Berg, M., Barranger, J. A., Sa Miranda, M. C., Tager, J. M. & Aerts, J. M. F. G. 1993a Role of pH in determining the cell-type specific residual activity of glucocerebrosidase in type 1 Gaucher disease. J. Clin. Invest. 91, 1167-1175.
65. Van Weely, S., Brandsma, M., Strijland, A., Tager, J. M. & Aerts, J. M. F. G. 1993b The existence of a non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim. Biophys. Acta 1181, 55-62.
66. Vellodi, A., Bembi, B., de Villemeur, T. B., Collin-Histed, T., Erikson, A., Mengel, E., Rolfs, A. & Tylki-Szymanska, A. 2001 Management of neuronopathic Gaucher disease: a European consensus. J. Inherit. Metab. Dis. 24, 319-327.